Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position PaperPractice Guideline Published on 2020-11-012022-10-04 Journal: Allergy [Category] 신약개발, [키워드] acute respiratory syndrome affecting Asymptomatic case caused Clinical management clinical manifestation clinician coronavirus Coronavirus disease 2019 Course COVID-19 COVID-19 pandemic desensitization Diagnosis differential diagnosis disease drug drug hypersensitivity reactions. highlight hypersensitivity reaction hypersensitivity reactions information knowledge management manifestation Mild occur off-label paper Patient Pneumonia position recommendations reported respiratory tract infection SARS-CoV-2 severe symptoms the disease Treatment [DOI] 10.1111/all.14439 PMC 바로가기 [Article Type] Practice Guideline
Frequent Hand Washing for COVID-19 Prevention Can Cause Hand Dermatitis: Management TipsDermatology Published on 2020-04-022022-10-31 Journal: Cureus [Category] COVID-19, [키워드] Activation Adverse adverse event allergic approach atopic dermatitis Can cause changes changes in community transmission condition Contact contact dermatitis contagious contaminated surfaces Coronavirus disease 2019 coughing COVID-19 deviate eczematous Effects epidermal hand hand dermatitis health system hygiene hypersensitivity reactions immune system impairment individual induce occur Occurrence pathophysiologic physical agent prevention preventive measure proinflammatory cytokines prolonged exposure resource respiratory route Spread subsequent therapeutic Transmission Vaccine virus washing washing hand [DOI] 10.7759/cureus.7506 PMC 바로가기 [Article Type] Dermatology
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial아바카비르, 지도부딘 또는 스타부딘을 아프리카 HIV 감염 소아용 정제로 사용(CHAPAS-3): 공개 라벨, 병렬 그룹, 무작위 대조 시험Articles Published on 2016-02-012022-09-06 Journal: The Lancet. Infectious Diseases [Category] Communicable Disease, [키워드] abacavir adverse event adverse events African analysed Antiretroviral therapy ART children clinical database Developing drugs dual efavirenz enrolled European finding Follow-up funding groups hazard ratio hypersensitivity hypersensitivity reactions immunological inhibitor Intention intention to treat ISRCTN registry Laboratory lamivudine less Lipodystrophy median median age nevirapine nucleoside occurred Open-label parallel-group partnership primary endpoint randomisation randomised controlled trial Randomised trial Registered responses stavudine suppression Tablet Toxicity Treatment Trial Uganda Viral Viral load Virological were excluded WHO zidovudine [DOI] 10.1016/S1473-3099(15)00319-9 PMC 바로가기 [Article Type] Articles